NEWS IN BRIEF Sagent acquires US facility with an eye on future biosimilar products 12-Mar-2019 By Staff reporter Sagent purchases Xellia’s FDA-approved site in North Carolina, which has capabilities to manufacture both small molecule and biologic products.